Pirfenidone Improves Idiopathic Pulmonary Fibrosis Survival Pirfenidone Improves Idiopathic Pulmonary Fibrosis Survival

Pirfenidone increased 3-year survival in patients with idiopathic pulmonary fibrosis, resulting in a 30% survival benefit compared with those not treated with antifibrotic agents, a study found.Medscape Medical News

Source: Medscape Medical News Headlines - January 9, 2019 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news